• Boule Diagnostics updated its India licensing agreement with Q-Line Biotech covering reagents, consumables, hematology analyzers.
• Revised terms aim to simplify the commercial structure, align incentives, support long-term growth in the installed base.
• India remains a key market, with public procurement programs and tenders expected over the coming year.
• Broader adoption of RFID-enabled lab workflows is expected to lift demand, supporting traceability and compliance requirements.
• Partnership builds on more than a decade of cooperation, with continued investment in service and customer support across India.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Boule Diagnostics AB published the original content used to generate this news brief on October 06, 2026, and is solely responsible for the information contained therein.